MERCK KGAA/ DE0006599905 /
1/8/2025 5:32:15 PM | Chg. -2.20 | Volume | Bid5:32:15 PM | Ask5:32:15 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
143.05EUR | -1.51% | 0 Turnover: - |
-Bid Size: - | -Ask Size: - | 18.49 bill.EUR | 1.54% | 22.04 |
GlobeNewswire
6/3/2024
Biolojic Design Enters into a Multi-Target Drug Discovery Collaboration with Merck KGaA, Darmstadt, ...
GlobeNewswire
5/29/2024
Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK) of its portfolio company EyeBio fo...
GlobeNewswire
5/29/2024
Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study
GlobeNewswire
5/7/2024
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...
GlobeNewswire
5/6/2024
Press Release Biocartis NV: Biocartis and Merck to Collaborate on Improving Patient Access to Person...
GlobeNewswire
3/4/2024
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Ger...
GlobeNewswire
12/21/2023
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...
GlobeNewswire
12/14/2023
ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development an...
GlobeNewswire
10/17/2023
ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA